- recruiting
OSPREY is a Post-market, Global, Multicentre, Observational, Prospective Registry.
The OSPREY Registry is looking at how a device called OncoSil™ works in people with locally advanced pancreatic cancer in normal hospital care. It watches how well the device performs and if there are any side effects when used with standard chemotherapy.
Spain · United Kingdom - not yet recruitingPHASE2
A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency.
This study is testing a new capsule, NHS7108, for people with Exocrine Pancreatic Insufficiency (EPI). It compares the new medicine to a standard treatment (Zenpep®) to see how safe it is and how well it helps the body digest food.
United States · Bulgaria · Hungary - recruitingPHASE2, PHASE3
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
This study looks at two drugs called dabrafenib and trametinib for various cancers with a specific gene change (BRAF V600). These drugs are already approved for some cancers and researchers want to see if they can help people with other rare cancers or cancers with this same change.
United Kingdom